Dana-Farber / Harvard Cancer Institute

Boston, Massachusetts 02215

0 studies enrolling now · 3 studies all time

What they study most

Anemia, Breast Neoplasms, Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Low to Intermediate-1 MDS, Myelodysplastic Syndromes, Myelodysplastic Syndromes (MDS), Pancreatic Neoplasms, Previously Untreated Pancreatic Ductal Adenocarcinoma, Relapsed/Refractory Pancreatic Ductal Adenocarcinoma

Studies at this site

• Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) — Completed
• Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma — Stopped early
• Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer — Completed